In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.

Latest From Francesca Bruce

Brexit Issues Lead NICE To Delay Methods Review

England’s health technology appraisal body, NICE, and the UK medicines regulator, the MHRA, are working together to align their process timelines so that access to medicines is “maintained and enhanced.”

Europe United Kingdom

Improve Access to RWD In Asia To Make RWE Viable

Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.

Asia Pacific China

Italy To Consult On Pricing Transparency Requirements

Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.

German Guidelines Seek To Boost Biosimilar Uptake

Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.

Biosimilars Regulation

European Regulatory Strategy ‘Should Prioritize Real World Evidence’

EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.

Europe Clinical Trials

Germany Sets Direction Of Travel With New Biosimilar Guidelines

Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in move towards increasing biosimilar uptake.

Europe Germany
See All
UsernamePublicRestriction

Register